Tags

Type your tag names separated by a space and hit enter

Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population.
Int J Geriatr Psychiatry 2007; 22(4):294-304IJ

Abstract

OBJECTIVES

To design and validate a new screening test for amnestic Mild Cognitive Impairment (A-MCI) and early stage Alzheimer's disease (AD).

METHODS

We develop a verbal episodic and semantic memory test: the Memory Alteration Test (M@T). Discriminative validity was assessed in a population sample of 400 aged individuals from primary care population centres in Barcelona, Spain, 50 patients with A-MCI according to Petersen et al. criteria, and 66 with early AD (Global Deterioration Scale-4 stage) according to the NINCDS-ADRDA criteria.

RESULTS

The M@T is quick, 5-min, and easy to administer and to score. M@T mean scores were significantly different between all groups: 41.4 (SD = 4.9) in the primary care population, 31.5 (SD = 3.9) in the A-MCI group and 21.8 (SD = 4.9) in early AD. A cut-off score of 37 points had a sensitivity of 96% and a specificity of 79% for A-MCI diagnosis (AUC = 0.932). A cut-off score of 28 points had a sensitivity of 92% and a specificity of 98% for early AD diagnosis (AUC = 0.99) and a sensitivity of 87 % and specificity of 82% to differentiate between A-MCI and AD patients.

CONCLUSION

The M@T provides efficient and valid screening for A-MCI and early stage AD, and discriminates between A-MCI and early AD patients.

Authors+Show Affiliations

Memory-Alzheimer Unit, Department of Neurology, Institute of Neurosciences, Hospital Clinic i Universitari de Barcelona, Institut d'Investigaciò Biomédica August Pi I Sunyer, Spain. jlmoli@clinic.ub.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16998781

Citation

Rami, L, et al. "Screening for Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease With M@T (Memory Alteration Test) in the Primary Care Population." International Journal of Geriatric Psychiatry, vol. 22, no. 4, 2007, pp. 294-304.
Rami L, Molinuevo JL, Sanchez-Valle R, et al. Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Int J Geriatr Psychiatry. 2007;22(4):294-304.
Rami, L., Molinuevo, J. L., Sanchez-Valle, R., Bosch, B., & Villar, A. (2007). Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. International Journal of Geriatric Psychiatry, 22(4), pp. 294-304.
Rami L, et al. Screening for Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease With M@T (Memory Alteration Test) in the Primary Care Population. Int J Geriatr Psychiatry. 2007;22(4):294-304. PubMed PMID: 16998781.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. AU - Rami,L, AU - Molinuevo,J L, AU - Sanchez-Valle,R, AU - Bosch,B, AU - Villar,A, PY - 2006/9/26/pubmed PY - 2007/12/13/medline PY - 2006/9/26/entrez SP - 294 EP - 304 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 22 IS - 4 N2 - OBJECTIVES: To design and validate a new screening test for amnestic Mild Cognitive Impairment (A-MCI) and early stage Alzheimer's disease (AD). METHODS: We develop a verbal episodic and semantic memory test: the Memory Alteration Test (M@T). Discriminative validity was assessed in a population sample of 400 aged individuals from primary care population centres in Barcelona, Spain, 50 patients with A-MCI according to Petersen et al. criteria, and 66 with early AD (Global Deterioration Scale-4 stage) according to the NINCDS-ADRDA criteria. RESULTS: The M@T is quick, 5-min, and easy to administer and to score. M@T mean scores were significantly different between all groups: 41.4 (SD = 4.9) in the primary care population, 31.5 (SD = 3.9) in the A-MCI group and 21.8 (SD = 4.9) in early AD. A cut-off score of 37 points had a sensitivity of 96% and a specificity of 79% for A-MCI diagnosis (AUC = 0.932). A cut-off score of 28 points had a sensitivity of 92% and a specificity of 98% for early AD diagnosis (AUC = 0.99) and a sensitivity of 87 % and specificity of 82% to differentiate between A-MCI and AD patients. CONCLUSION: The M@T provides efficient and valid screening for A-MCI and early stage AD, and discriminates between A-MCI and early AD patients. SN - 0885-6230 UR - https://www.unboundmedicine.com/medline/citation/16998781/Screening_for_amnestic_mild_cognitive_impairment_and_early_Alzheimer's_disease_with_M@T__Memory_Alteration_Test__in_the_primary_care_population_ L2 - https://doi.org/10.1002/gps.1672 DB - PRIME DP - Unbound Medicine ER -